Reporter-encoding Oncolytic Vaccinia Virus Western Reserve (ΔE3L), p7.5k-(EGFP) (RepOV-0008WQ)

This product is a EGFP encoding oncolytic vaccinia virus, which is based on VACV-WR with E3L deleted.Protein E3 plays a role in the inhibition of multiple cellular antiviral responses activated by dsRNA, such as inhibition of PKR activation, apoptosis, and IFN-mediated antiviral activities.The TNFSF9 has been shown to reactivate anergic T lymphocytes in addition to promoting T lymphocyte proliferation.The deletion of E3L and oncolytic-rendered modifications could enhance an immune response to a poxvirus vaccine.This product can be used in oncolytic virotherapy research and vaccinie application.

Specifications
Family Poxviridae
Species Vaccinia virus
Serotype Western Reserve
Backbone VACV-WR(ΔE3L)
Backbone Background VACV-WR strain derived from Wyeth through passaging in mice and shown high tumor selectivity and strong oncolytic effect in mouse models.The engineered VACV-WR could further enhance the immune activity and the efficacy of cancer therapies.
Gene Modification ΔE3L
Promoter p7.5k
Transgene EGFP
Type of Transgene Reporter gene
Related Target/Protein Enhanced green fluorescent protein
Capsid Modification None
Titer >1*10^8 PFU
Related Diseases Breast cancer, Prostate cancer, Colon cancer, Cancer vaccine
Transgene
Alternative Names EGFP, egfp, enhanced green fluorescent protein
Gene ID 20473140
Information
Introduction EGFP, derived from Aequorea victoria, is a unique GFP variant which contains chromophore mutations that make the protein 35 times brighter than wild-type GFP, and is codon-optimized for higher expression in mammalian cells. These changes in the GFP coding sequence provide an enhanced GFP (EGFP) that greatly increases the sensitivity of the reporter protein.
All services and products are for lab research only, not for any clinical use.

Other products

Contact Us

  • 1-631-466-5530
    44-207-097-1828
  • 1-631-207-8356

Contact Us

Copyright © 2007 - 2020 Creative Biolabs. All Rights Reserved